Why Aerie Pharmaceuticals (AERI) Stock Is Soaring Today

NEW YORK (TheStreet) -- Aerie Pharmaceuticals  (AERI) soared Wednesday after its once-daily glaucoma eye drop Roclatan met all of its clinical endpoints in a phase 2b trial.

The company expects to submit its New Drug Application filing in mid-2016.

The stock was up 26.01% to $26.50 at 12:40 p.m.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AERI Price Chart

AERI Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

4 Small-Cap Biotech Stars